Arax Advisory Partners’s Astria Therapeutics ATXS Stock Holding History

Arax Advisory Partners’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7	Closed	-$92	–	3815
2025 Q4	$92	Sell	7 -13	-65%	-$155	﹤0.01%	3841
2025 Q3	$145	Buy	+20	New	+$135	﹤0.01%	3474
2025 Q1	–	Sell	-65	Closed	-$582	–	2690
2024 Q4	$582	Buy	+65	New	+$690	﹤0.01%	2302

Arax Advisory Partners's ATXS Position: Q1 2026 in Review

Arax Advisory Partners sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 7 shares — an estimated $92 sold.

Arax Advisory Partners first reported a position in ATXS in Q4 2024 and held it in 3 quarters. The position peaked at $582 in Q4 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Arax Advisory Partners reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Arax Advisory Partners sold 7 Astria Therapeutics shares in Q1 2026, an estimated $92.
Arax Advisory Partners first reported a position in Astria Therapeutics in Q4 2024 and held it in 3 quarters.
Arax Advisory Partners's Astria Therapeutics position peaked at $582 in Q4 2024.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.